Recent progress of nanodrugs for treating ulcerative colitis by targeting macrophage
10.3760/cma.j.cn101480-20231121-00068
- VernacularTitle:靶向巨噬细胞纳米药物治疗溃疡性结肠炎的研究进展
- Author:
Chengjun SONG
1
;
Jiamin WU
1
;
Fangyu WANG
1
Author Information
1. 南京大学医学院附属金陵医院消化内科，南京 210002
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Macrophage;
Target;
Nanodrugs
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(4):300-303
- CountryChina
- Language:Chinese
-
Abstract:
Ulcerative colitis (UC) is an idiopathic and relapsing inflammatory bowel disease. Previous research has uncovered that macrophages play an indispensable role during the progression of UC. Macrophages in the mucus are stimulated via upstream cytokines or ligands from microorganisms and secrete numerous inflammatory cytokines to exacerbate the colitis. Consequently, precisely modulating macrophages has been an intriguing strategy in UC treatment recently. With the superiority of high efficiency, less toxicity, and sustained release, exploring macrophage-targeted nanodrugs has already become a mainstream approach in UC therapeutics. This review summarizes the strategy of targeting macrophages with nanodrugs and the potential biological mechanisms for UC treatment.
